John A. Kosteva, MD

Omar Elghawy 1, Adam Barsouk 1, Jonathan H Sussman 1, Benjamin A Bleiberg 1, Lauren Reed-Guy 1, Christopher D'Avella 1, Aditi Singh 1, Christine Ciunci 1, Kyle Robinson 1, John Kosteva 1, Corey Langer 1, Roger B Cohen 1, Charu Aggarwal 1, Melina Marmarelis 1, Lova Sun 1 Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC , JTO Clin Res Rep. 2025 May 26;6(9):100851. doi: 10.1016/j.jtocrr.2025.100851. eCollection 2025 Sep., 6(9): 2025,100851

Omar Elghawy 1, Adam Barsouk 1, Lauren Reed-Guy 1, Margaret Stalker 1, Jonathan Sussman 1, Kyle Robinson 1, John Kosteva 1, Aditi Singh 1, Roger B Cohen 1, Corey Langer 1, Christine Ciunci 1, Christopher D'Avella 1, Lova Sun 1, Melina E Marmarelis 1, Charu Aggarwal 2 Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy , Clin Lung Cancer . 2025 Mar;26(2):158-163.e2. doi: 10.1016/j.cllc.2024.11.014., 26(2): 2025,158-163

Marmarelis ME, Scholes DG, McWilliams TL, Hwang WT, Kosteva J, Costello MR, Sun L, Singh AP, Lau-Min KS, Doucette A, Gabriel PE, Martella AO, Roy MA, Thompson JC, Cohen RB, Dougherty DW, Shulman LN, Langer CJ, Bekelman JE, Carpenter EL, Aggarwal C. Electronic Medical Record–Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non–Small Cell Lung Cancer: Results From a Prospective Clinical Trial , JCO Oncol Pract. 2024 Jul 3:OP2400070. doi: 10.1200/OP.24.00070, 00: 2024,1-9

Barsouk A, Friedes C, Iocolano M, Doucette A, Cohen RB, Robinson KW, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Levin WP, Cengel KA, Bradley JD, Feigenberg SJ, Sun L, Aggarwal C, Langer CJ, Yegya-Raman N. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation , Clin Lung Cancer. 2024 May;25(3):e161-e171. doi: 10.1016/j.cllc.2023.12.009. Epub 2023 Dec 22., 25(3): 2024,161-171

Aggarwal C, Marmarelis ME, Hwang WT, Scholes DG, McWilliams TL, Singh AP, Sun L, Kosteva J, Costello MR, Cohen RB, Langer CJ, Doucette A, Gabriel PN, Shulman LN, Rendle KA, Thompson JC, Bekelman JE, Carpenter EL. Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer , JCO Precis Oncol. 2023 Jul;7:e2300191. doi: 10.1200/PO.23.00191., 7: 2023,e2300191

Yegya-Raman N, Friedes C, Sun L, Iocolano M, Kim KN, Doucette A, Cohen RB, Robinson KW, Levin WP, Cengel KA, Lally B, Agarwal M, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Aggarwal C, Berman AT, Langer CJ, Feigenberg SJ. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System , Clin Lung Cancer. 2023 Jul;24(5):474-482. doi: 10.1016/j.cllc.2023.03.013. Epub 2023 Apr 3.: 2023

Charu Aggarwal, Melina Elpi Marmarelis, Wei-Ting Hwang, Dylan G. Scholes, Tara McWilliams, Aditi Puri Singh, Lova Sun, John A. Kosteva, Michael Robert Costello, Roger B. Cohen, Corey J. Langer, Peter Edward Gabriel, Lawrence N. Shulman, Jeffrey C. Thompson, Erica L. Carpenter Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer , 10.1200/JCO.2022.40.16_suppl.9022 Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 9022-9022., 40(16): 2022

Nikhil Yegya-Raman, Cole Friedes, Lova Sun, Melina Elpi Marmarelis, William C. Levin, Keith A. Cengel, Brian Lally, Christopher Davella, John A. Kosteva, Aditi Puri Singh, Roger B. Cohen, Charu Aggarwal, Christine Ciunci, Abigail T. Berman, Corey J. Langer, Steven J. Feigenberg Checkpoint inhibitor consolidation after definitive chemoradiation for stage III non–small cell lung cancer: Real-world experience in a large academic health system , 10.1200/JCO.2022.40.16_suppl.8523 Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 8523-8523., 40(16): 2022

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. , Lung Cancer. 2017 Apr;106:1-7. doi: 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25.: 2017

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. , Clin Cancer Res. 2016 Dec 1;22(23):5772-5782. Epub 2016 Sep 6.: 2016